Skip to main content
SpringerLink
Log in

Ustekinumab does not increase risk of CVD in patients with psoriasis

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • de Brito M, et al. Cardiovascular Safety of Biologics Targeting Interleukin (IL)-12 and/or IL-23: What Does the Evidence Say? American Journal of Clinical Dermatology : 22 Jul 2021. Available from: URL: http://doi.org/10.1007/s40257-021-00612-9

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ustekinumab does not increase risk of CVD in patients with psoriasis. Reactions Weekly 1867, 14 (2021). https://doi.org/10.1007/s40278-021-00074-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-00074-4

Search

Navigation